BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 37638025)

  • 1. Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profiles.
    Govindarajan A; Salgia NJ; Li H; Castro DV; Mirzapoiazova T; Armstrong B; Zhao D; Mercier BD; Dizman N; Chawla N; Zengin Z; Meza L; Tripathi N; Sayegh N; Chehrazi-Raffle A; Tripathi A; Pal SK
    Front Immunol; 2023; 14():1182581. PubMed ID: 37638025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma.
    Kroeze SG; Bijenhof AM; Bosch JL; Jans JJ
    Cancer Biomark; 2010; 7(6):261-8. PubMed ID: 21694464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spatial heterogeneity of tumor microenvironment influences the prognosis of clear cell renal cell carcinoma.
    Zhang D; Ni Y; Wang Y; Feng J; Zhuang N; Li J; Liu L; Shen W; Zheng J; Zheng W; Qian C; Shan J; Zhou Z
    J Transl Med; 2023 Jul; 21(1):489. PubMed ID: 37474942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of papillary versus clear cell renal cell carcinoma varies significantly in non-metastatic disease.
    Wagener N; Edelmann D; Benner A; Zigeuner R; Borgmann H; Wolff I; Krabbe LM; Musquera M; Dell'Oglio P; Capitanio U; Klatte T; Cindolo L; May M; Brookman-May SD;
    PLoS One; 2017; 12(9):e0184173. PubMed ID: 28934212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of histologic subtype and sarcomatoid transformation on metastasis in renal cell carcinoma: a single institute experience in 149 patients.
    Tirumani SH; Souza D; Krajewski KM; Jagannathan JP; Ramaiya NH; Shinagare AB
    Abdom Radiol (NY); 2016 Feb; 41(2):295-302. PubMed ID: 26867911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of molecular subtypes based on chromatin regulator and tumor microenvironment infiltration characterization in papillary renal cell carcinoma.
    Tang Q; Pan D; Xu C; Chen L
    J Cancer Res Clin Oncol; 2023 Jan; 149(1):231-245. PubMed ID: 36404389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Papillary vs clear cell renal cell carcinoma. Differentiation and grading by iodine concentration using DECT-correlation with microvascular density.
    Marcon J; Graser A; Horst D; Casuscelli J; Spek A; Stief CG; Reiser MF; Rübenthaler J; Buchner A; Staehler M
    Eur Radiol; 2020 Jan; 30(1):1-10. PubMed ID: 31278580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery-Results from RECUR Consortium.
    Abu-Ghanem Y; Powles T; Capitanio U; Beisland C; Järvinen P; Stewart GD; Gudmundsson EO; Lam TB; Marconi L; Fernandéz-Pello S; Nisen H; Meijer RP; Volpe A; Ljungberg B; Klatte T; Dabestani S; Bex A
    Eur Urol Oncol; 2021 Jun; 4(3):473-482. PubMed ID: 33109495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histologic subtype needs to be considered after partial nephrectomy in patients with pathologic T1a renal cell carcinoma: papillary vs. clear cell renal cell carcinoma.
    Yoo S; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Kim CS
    J Cancer Res Clin Oncol; 2017 Sep; 143(9):1845-1851. PubMed ID: 28451753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy.
    Büttner FA; Winter S; Stühler V; Rausch S; Hennenlotter J; Füssel S; Zastrow S; Meinhardt M; Toma M; Jerónimo C; Henrique R; Miranda-Gonçalves V; Kröger N; Ribback S; Hartmann A; Agaimy A; Stöhr C; Polifka I; Fend F; Scharpf M; Comperat E; Wasinger G; Moch H; Stenzl A; Gerlinger M; Bedke J; Schwab M; Schaeffeler E
    Genome Med; 2022 Sep; 14(1):105. PubMed ID: 36109798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Characterization of TFE3-Rearranged Renal Cell Carcinoma: A Comparative Study With Papillary and Clear Cell Renal Cell Carcinomas.
    Wei S; Krause HB; Geynisman DM; Elliott A; Kutikov A; Uzzo RG; Pei J; Barata P; Carneiro B; Heath E; Ryan C; Farrell A; Nabhan C; Ali-Fehmi R; Naqash AR; Argani P; McKay RR
    Mod Pathol; 2024 Feb; 37(2):100404. PubMed ID: 38104891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MR characteristics of mucinous tubular and spindle cell carcinoma (MTSCC) of the kidney: comparison with clear cell and papillary subtypes of renal cell carcinoma.
    Takahashi H; Vikram R; Jimenez RE; Bolan CW; Kawashima A; Karam JA; Takahashi N
    Abdom Radiol (NY); 2021 Nov; 46(11):5250-5259. PubMed ID: 34338814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor grade estımatıon of clear cell and papıllary renal cell carcınomas usıng contrast-enhanced MDCT and FSE T2 weıghted MR ımagıng: radıology-pathology correlatıon.
    Halefoglu AM; Ozagari AA
    Radiol Med; 2021 Sep; 126(9):1139-1148. PubMed ID: 34100169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An epidemiological and clinicopathological study of type 1 vs. type 2 morphological subtypes of papillary renal cell carcinoma- results from a nation-wide study covering 50 years in Iceland.
    Runarsson TG; Bergmann A; Erlingsdottir G; Petursdottir V; Heitmann LA; Johannesson A; Asbjornsson V; Axelsson T; Hilmarsson R; Gudbjartsson T
    BMC Urol; 2024 May; 24(1):105. PubMed ID: 38741053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole lesion quantitative CT evaluation of renal cell carcinoma: differentiation of clear cell from papillary renal cell carcinoma.
    Chen F; Huhdanpaa H; Desai B; Hwang D; Cen S; Sherrod A; Bernhard JC; Desai M; Gill I; Duddalwar V
    Springerplus; 2015; 4():66. PubMed ID: 25694862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Percutaneous Cryoablation of Solitary, Sporadic Renal Cell Carcinoma: Outcome Analysis Based on Clear-Cell versus Papillary Subtypes.
    Haddad MM; Schmit GD; Kurup AN; Schmitz JJ; Boorjian SA; Geske J; Thompson RH; Callstrom MR; Atwell TD
    J Vasc Interv Radiol; 2018 Aug; 29(8):1122-1126. PubMed ID: 29887184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differentiating papillary type I RCC from clear cell RCC and oncocytoma: application of whole-lesion volumetric ADC measurement.
    Paschall AK; Mirmomen SM; Symons R; Pourmorteza A; Gautam R; Sahai A; Dwyer AJ; Merino MJ; Metwalli AR; Linehan WM; Malayeri AA
    Abdom Radiol (NY); 2018 Sep; 43(9):2424-2430. PubMed ID: 29520425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Etiologic heterogeneity of clear-cell and papillary renal cell carcinoma in the Netherlands Cohort Study.
    van de Pol JAA; George L; van den Brandt PA; Baldewijns MMLL; Schouten LJ
    Int J Cancer; 2021 Jan; 148(1):67-76. PubMed ID: 32638386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological and survival analysis of clinically advanced papillary and chromophobe renal cell carcinoma.
    Kaldany A; Paulucci DJ; Kannappan M; Beksac AT; Anastos H; Okhawere K; Sfakianos JP; Badani KK
    Urol Oncol; 2019 Oct; 37(10):727-734. PubMed ID: 31174958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrative Analysis of Immune-Related Genes in the Tumor Microenvironment of Renal Clear Cell Carcinoma and Renal Papillary Cell Carcinoma.
    Zheng B; Xie F; Cheng F; Wang J; Yao Z; He W; Niu Z
    Front Mol Biosci; 2021; 8():760031. PubMed ID: 34888353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.